



JCE20 Rec'd PCT/PTO 30 MAY 2002 CT #

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents

Washington, D.C. 20231 on May 13, 2002

David Saliwanchik

David R. Saliwanchik, Patent Attorney

INFORMATION DISCLOSURE  
STATEMENT

Patent Application

Docket No. GJE-88

Serial No. 10/070,568

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : You-Min Feng, You-Shang Zhang  
Serial No. : 10/070,568  
Conf. No. :  
Filed : March 8, 2002  
For : Monomeric Analogues of Human Insulin

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

The above-identified patent application was filed in the U.S. Patent Office as a national application under 35 USC §371. In accordance with 37 CFR §1.56, the Applicants hereby request that the references cited in the international search report and listed on the attached form PTO-1449 be made of record and considered in the examination of the subject application. The Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

David Saliwanchik

David R. Saliwanchik

Patent Attorney

Registration No. 31,794


Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address : 2421 N.W. 41st Street, Suite A-1  
Gainesville, Florida 32606-6669

DRS/la

Attachment: Form PTO-1449; and copies of references cited therein



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Applicant Number	10/070,568	
			Filing Date	March 8, 2002	
			First Named Inventor	You-Min Feng	
			Art Unit		
Examiner Name					
Attorney Docket Number	GJE-88				
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-4,916,212	04-10-1990	Markussen <i>et al.</i>	
	U2	US-5,618,913	04-08-1997	Brange <i>et al.</i>	
	U3	US-5,952,297	09-14-1999	De Felippis <i>et al.</i>	
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	F1	0 046 979 A	03-10-1982	Hoechst AG		
	F2	0 214 826 A2	03-18-1987	Novo Industri A/S		
	F3	0 291 863 A	11-23-1988	Hoechst AG		
	F4	93112586.3 (application)	04-26-1993	Shanghai Inst. of Biochem.		
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/070,568
Filing Date	March 8, 2002
First Named Inventor	You-Min Feng
Group Art Unit	
Examiner Name	
Attorney Docket Number	GJE-88

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	BRANGE, J. <i>et al.</i> (June 16, 1988) "Monomeric insulins obtained by protein engineering and their medical implications" <i>Nature</i> (London) 333:679-682.	
	R2	JENSEN, IVAN <i>et al.</i> (1991) "Scintigraphic studies in rats: kinetics of insulin analogs covering wide range of receptor affinities" <i>Chemical Abstracts Service</i> , Database accession no. 115:224155CA (Diabetes, 1991, 40(5):628-32) abstract only.	
	R3	KRISTENSEN, CLAUS <i>et al.</i> (May 16, 1997) "Alanine Scanning Mutagenesis of Insulin" <i>The Journal of Biological Chemistry</i> 272(20):12978-12983.	
	R4	NOBLE, SARA L., ELIZABETH JOHNSTON, BILL WALTON (January 15, 1998) "Insulin Lispro: A Fast-Acting Insulin Analog" <i>In: The American Academy of Family Physicians</i> .	
	R5	WANG, QIONG-QING <i>et al.</i> (November 18, 1996) "Studies on receptor binding site of insulin: the hydrophobic B12Val can be substituted by hydrophilic Thr" <i>Chemical Abstracts</i> 125(21), abstract no. 266145 (Biochem. Mol. Biol. Int. 39(6):1245-1254) abstract only.	
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.